Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Inclusion Criteria:

• Must weigh at least 35 kilograms (kg).

• An Eastern Cooperative Oncology Group (ECOG) performance status <= 2.

• Life expectancy of >= 12 weeks.

• Laboratory values meeting protocol criteria.

• QT interval corrected for heart rate < 470 msec (using Fridericia's correction), andno clinically significant electrocardiographic findings.

• Measurable disease defined by RECIST 1.1 criteria.

For Monotherapy and Combination Dose Escalation:

• Participants with histologically or cytologically proven metastatic or locallyadvanced tumors, for which no effective standard therapy exists, or where standardtherapy has failed. Participants must have received at least 1 prior systemicanticancer therapy for the indication being considered.

For Monotherapy Dose Expansion only:

• Participants must have received at least 1 prior line containing PD-1/PD-L1 targetedtherapy with a best response by RECIST v1.1 of CR/PR/stable (any duration) or stabledisease (for greater than 6 months); AND

• Must have been previously treated with 1 or more prior lines of therapy in thelocally advanced or metastatic setting with the following tumor types:

• Relapsed/refractory HNSCC

• Relapsed/refractory NSCLC

• Advanced ccRCC

For PD-1 Targeting Agent Combination Dose Expansion only:

• For the following tumor types, subject must have received at least 1 prior linecontaining PD-1/PD-L1 targeted therapy with response by RECIST v1.1 of CR/PR (anyduration) or stable disease (for greater than 6 months):

• Relapsed HNSCC

• Relapsed NSCLC

• Relapsed Advanced ccRCC

• For the following tumor types, subject must have received at least 1 prior linecontaining PD-1/PD-L1 targeted therapy and have had disease progression withPD-1/PD-L1 targeted therapy:

• Locally Advanced or metastatic MSI-H tumors

For VEGFR TKI Combination Dose Expansion only:

• Relapsed advance ccRCC with no more than 1 prior VEGFR TKI

• Participants no recent history of hemorrhage, including hemoptysis, hematemesis, ormelena

• Participants with poorly controlled hypertension are excluded.

Exclusion Criteria:

• Untreated brain or meningeal metastases (i.e., subjects with history of metastasesare eligible provided they do not require ongoing steroid treatment and have shownclinical and radiographic stability for at least 28 days after definitive therapy)

• Unresolved Grade 2 or higher toxicities related to previous anticancer therapyexcept alopecia.

• Unresolved Grade 2 or higher peripheral neuropathy.

• History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)infection.

• Recent history (within 6 months) of congestive heart failure (defined as New YorkHeart Association, Class 2 or higher), ischemic cardiovascular event, pericarditis,or clinically significant pericardial effusion or arrythmia.

• Recent history (within 6 months) of Childs-Pugh B or C classification of liverdisease.

• History of clinically significant medical and/or psychiatric conditions or any otherreason that, in the opinion of the investigator, would interfere with the subject'sparticipation in this study or would make the subject an unsuitable candidate toreceive study drug.

• History of uncontrolled, clinically significant endocrinopathy.

• Known gastrointestinal disorders making absorption of oral medications problematic;subject must be able to swallow capsules.

• If treated with a PD-1/aPD-L1 targeting or other immune-oncology agents in the past,excluded if had prior pneumonitis, prior Grade 3 or higher immune mediated toxicity,hypersensitivity to administered drug or drug related toxicity requiringdiscontinuation.

• Active autoimmune disease requiring systemic treatment in past 2-years (exceptionsfor endocrinopathies, vitiligo or atopic conditions).

• History of solid organ transplant or allogeneic stem cell transplant.

• History of other malignancy, with the following exceptions:advanced tumors, for which no effective standard therapy exists, or where standard&#xd;therapy has failed. Participants must have received at least 1 prior systemic&#xd;anticancer therapy for the indication being considered.&#xd; &#xd; For Monotherapy Dose Expansion only:&#xd; &#xd;

• Participants must have received at least 1 prior line containing PD-1/PD-L1 targeted&#xd;therapy with a best response by RECIST v1.1 of CR/PR/stable (any duration) or stable&#xd;disease (for greater than 6 months); AND&#xd; &#xd;

• Must have been previously treated with 1 or more prior lines of therapy in the&#xd;locally advanced or metastatic setting with the following tumor types:&#xd; &#xd;

• Relapsed/refractory HNSCC&#xd; &#xd;

• Relapsed/refractory NSCLC&#xd; &#xd;

• Advanced ccRCC&#xd; &#xd; For PD-1 Targeting Agent Combination Dose Expansion only:&#xd; &#xd;

• For the following tumor types, subject must have received at least 1 prior line&#xd;containing PD-1/PD-L1 targeted therapy with response by RECIST v1.1 of CR/PR (any&#xd;duration) or stable disease (for greater than 6 months):&#xd; &#xd;

• Relapsed HNSCC&#xd; &#xd;

• Relapsed NSCLC&#xd; &#xd;

• Relapsed Advanced ccRCC&#xd; &#xd;

• For the following tumor types, subject must have received at least 1 prior line&#xd;containing PD-1/PD-L1 targeted therapy and have had disease progression with&#xd;PD-1/PD-L1 targeted therapy:&#xd; &#xd;

• Locally Advanced or metastatic MSI-H tumors&#xd; &#xd; For VEGFR TKI Combination Dose Expansion only:&#xd; &#xd;

• Relapsed advance ccRCC with no more than 1 prior VEGFR TKI&#xd; &#xd;

• Participants no recent history of hemorrhage, including hemoptysis, hematemesis, or&#xd;melena&#xd; &#xd;

• Participants with poorly controlled hypertension are excluded.&#xd; &#xd; Exclusion Criteria:&#xd; &#xd;

• Untreated brain or meningeal metastases (i.e., subjects with history of metastases&#xd;are eligible provided they do not require ongoing steroid treatment and have shown&#xd;clinical and radiographic stability for at least 28 days after definitive therapy)&#xd; &#xd;

• Unresolved Grade 2 or higher toxicities related to previous anticancer therapy&#xd;except alopecia.&#xd; &#xd;

• Unresolved Grade 2 or higher peripheral neuropathy.&#xd; &#xd;

• History of hepatitis B, hepatitis C, or human immunodeficiency virus (HIV)&#xd;infection.&#xd; &#xd;

• Recent history (within 6 months) of congestive heart failure (defined as New York&#xd;Heart Association, Class 2 or higher), ischemic cardiovascular event, pericarditis,&#xd;or clinically significant pericardial effusion or arrythmia.&#xd; &#xd;

• Recent history (within 6 months) of Childs-Pugh B or C classification of liver&#xd;disease.&#xd; &#xd;

• History of clinically significant medical and/or psychiatric conditions or any other&#xd;reason that, in the opinion of the investigator, would interfere with the subject's&#xd;participation in this study or would make the subject an unsuitable candidate to&#xd;receive study drug.&#xd; &#xd;

• History of uncontrolled, clinically significant endocrinopathy.&#xd; &#xd;

• Known gastrointestinal disorders making absorption of oral medications problematic;&#xd;subject must be able to swallow capsules.&#xd; &#xd;

• If treated with a PD-1/aPD-L1 targeting or other immune-oncology agents in the past,&#xd;excluded if had prior pneumonitis, prior Grade 3 or higher immune mediated toxicity,&#xd;hypersensitivity to administered drug or drug related toxicity requiring&#xd;discontinuation.&#xd; &#xd;

• Active autoimmune disease requiring systemic treatment in past 2-years (exceptions&#xd;for endocrinopathies, vitiligo or atopic conditions).&#xd; &#xd;

• History of solid organ transplant or allogeneic stem cell transplant.&#xd; &#xd;

• History of other malignancy, with the following exceptions:&#xd;

• No known active disease present within >= 3 years before first dose of studytreatment and felt to be at low recurrence by investigator.

• Adequately treated non-melanoma skin cancer or lentigo maligna without evidenceof disease.

• Adequately treated carcinoma in situ without evidence of disease.

• History of interstitial lung disease or pneumonitis.

• Major surgery <= 28 days prior to first dose of study drug

• Known active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionper local testing practices.